Zobrazeno 1 - 10
of 265
pro vyhledávání: ''
Autor:
N. Zanaletti, Susana Roselló Keränen, Debora Ierinò, Riccardo Giampieri, Michele De Tursi, Fabio Gelsomino, Ingrid Garajová, Alessio Cortellini, P. Vitale, Pasquale Lombardi, Emanuela Dell'Aquila, Teresa Troiani, Silvana Leo, Andrea Spallanzani, Giampiero Porzio, Ilaria Depetris, Federica De Galitiis, Olga Venditti, Angelica Petrillo, Michela Roberto, Francesca Di Pietro, Corrado Ficorella, Olga Nigro, Michele Ghidini, Roberto Filippi, Giampaolo Tortora, Antonio Avallone, Katia Cannita, Nicola Tinari, Gian Paolo Spinelli, Cristina Morelli, Lisa Salvatore, Giacomo Aimar, Fulgenzi Claudia, Alessandro Parisi, M. Ribelli, Valeria Zurlo, Federica Zoratto, Carla D'Orazio
Publikováno v:
Clinical Colorectal Cancer
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
BACKGROUND: Doublets plus antiepidermal growth factor receptors monoclonal antibodies (EGFRi) are widely considered the preferable first-line regimen in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC), resulting superi
Autor:
Huabin Hu, Weiwei Li, Xiaoyu Xie, Jianxia Li, Miaomiao Ding, Jianwei Zhang, Zehua Wu, Jiayu Ling, Yue Cai, Yanhong Deng
Publikováno v:
Clinical Colorectal Cancer. 20:e240-e248
To evaluate the predictive implications and prognosis of mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment.Individual patient data of LARC patients from 3 prospective clinical trials was ana
Autor:
Hans-Joachim Schmoll, Aimery de Gramont, Norman Wolmark, Greg Yothers, Einat Shacham-Shmueli, Ofer Margalit, Qian Shi, André Thierry, Daniel G. Haller, Manel Rakez, Ben Boursi
Publikováno v:
Clinical Colorectal Cancer. 20:130-136
Background The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) pooled analysis compared 3 to 6 months of adjuvant chemotherapy for stage III colon cancer. Patients were classified into low risk and high risk, suggesting low-risk pat
Publikováno v:
Clin Colorectal Cancer
Oxaliplatin-induced immune thrombocytopenia is a rare manifestation of oxaliplatin hypersensitivity, presenting as an acute onset of severe thrombocytopenia after oxaliplatin administration. No standard therapeutic approach outside of permanent disco
Autor:
Ji Yeon Baek, Young Suk Park, Sang-Hee Cho, Tae Won Kim, You Jin Chun, Joong Bae Ahn, Minkyu Jung, Keun Wook Lee, Seong Geun Kim, Seung Hoon Beom, Chong Woo Chu, Soojung Hong, Sang Joon Shin
Publikováno v:
Clinical Colorectal Cancer. 19:e140-e150
Introduction Whether patients with resectable colorectal liver metastases (CRLM) gain a survival benefit from perioperative chemotherapy remains controversial. The benefit of including bevacizumab in chemotherapy also remains unclear. Material and Me
Autor:
Åsa Ofigsbø, Stein Kaasa, Morten Brændengen, Hanne Frydenberg, Hanne Skoglund, Marianne Grønlie Guren, Nina K. Harsem
Publikováno v:
Clinical Colorectal Cancer. 19:141-144
Publikováno v:
Clin Colorectal Cancer
Background Metastatic microsatellite instability-high (MSI-H) colorectal cancer (CRC) is one of the rare gastrointestinal tumors where immune checkpoint inhibitors (ICIs) have a defined therapeutic role. Single-agent nivolumab, single-agent pembroliz
Autor:
Hui Wang, Xiaojian Wu, Jian Zheng, Jiayu Ling, Jian Xiao, Yanhong Deng, Dianke Chen, Feng Lin, Chen Shuang, Junsheng Peng, Huabin Hu, Jianping Wang, Lei Wang, Yue Cai, Jianwei Zhang, Zhiyang Zhou, Donglin Ren, Yan Zhang, Ping Lan, Meijin Huang, Liang Kang
Publikováno v:
Clinical Colorectal Cancer. 18:238-244
Introduction Although neoadjuvant chemo-radiotherapy (CRT) achieves low local recurrence rates in locally advanced rectal cancer (LARC), it raises a lot of concerns about long-term anal and sexual functions. We explored the efficacy of preoperative c
Autor:
Christina Bamia, Epaminontas Samantas, Georgia Kafiri, Dimitrios Bafaloukos, George Fountzilas, Sofia Chrisafi, Ioannis Efstratiou, Dimitrios Pectasides, Kyriaki Papadopoulou, Iliada Bombolaki, George Pentheroudakis, Thomas Makatsoris, Leonidas Mavroeidis, Georgia-Angeliki Koliou, Kyriakos Chatzopoulos, Kalliopi Petraki, Helen P. Kourea, George Papatsibas, Vassiliki Kotoula, Pavlos Papakostas, Davide Mauri
Publikováno v:
Clinical Colorectal Cancer. 18:e370-e384
Background Alternative splicing of vascular endothelial growth factor A (VEGFA) results in VEGFAxxxb antiangiogenic isoforms that fail to activate angiogenesis. Bevacizumab, widely used in patients with metastatic colorectal cancer (CRC), binds both
Autor:
Zsofia K. Stadler, Philip B. Paty, Lajhem Cambridge, Neil H. Segal, Jose G. Guillem, Julio Garcia-Aguilar, S.Y. Ng, Leonard B. Saltz, Garrett M. Nash, Kathryn L. Colborn, Martin R. Weiser, Karyn A. Goodman, Andrea Cercek, Diane Reidy-Lagunes
Publikováno v:
Clin Colorectal Cancer
Initial treatment with either neoadjuvant chemoradiation (CRT) or induction FOLFOX (5-Fluorouracil, leucovorin, and oxaliplatin) chemotherapy followed by CRT is considered standard treatment for locally advanced rectal cancer. We compared patient-rep